OR WAIT null SECS
Financial commitment is predicted to more than double the biopharma site’s manufacturing capabilities
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, will be investing approximately $533 million into its UK facility in Billingham, Teesside. This investment package provided by the Fujifilm Corporation subsidiary is expected to more than double the site’s development and manufacturing footprint, and is anticipated to create up to 350 highly-skilled jobs, the CDMO notes. The new facilities plan to be operational by late 2023.
The multi-modal campus will feature two new state-of-the-art facilities—a viral gene therapy good manufacturing practice (GMP) facility and a GMP mammalian cell culture facility—and is a component of the $797 million global capital investment package initially outlined by Fujifilm Corp. back in June of this year.
“ … With a strong growing demand for microbial, cell culture and viral gene therapy services, we are adding the capacity and latest technologies within one campus to offer a range of modalities to build an offering that will deliver novel promising treatments to patients for years to come,” says Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies.